SearcharxivSearch

arXiv subjects

Yuqing Xu

Publications and source records attributed to Yuqing Xu.

2 recordsLinked to original sources

Testing for Serial Independence via Auto Hilbert-Schmidt Independence Criterion

We develop a Hilbert--Schmidt independence criterion (HSIC)-based framework for testing serial independence in strictly stationary time series. The proposed auto Hilbert--Schmidt independence criterion (AutoHSIC) measures dependence between an observation and its lagged counterpart, providing a kernel-based approach to detecting nonlinear serial dependence. The empirical AutoHSIC statistic is a lagged U-statistic constructed from overlapping observations, and hence inherits temporal dependence even under the i.i.d. null. Its asymptotic analysis therefore differs from standard i.i.d. HSIC theory and must account for degeneracy under the null. We establish the limiting behaviour of the resulting single-lag and portmanteau tests under the null and under fixed alternatives. Since the limiting null distribution is non-pivotal, we develop a wild bootstrap procedure for critical value approximation and prove its asymptotic validity. The framework is further extended to residual-based model diagnostics, where parameter estimation affects the null distribution. Simulations and empirical applications illustrate its ability to detect nonlinear serial dependence in multivariate, functional and matrix time series.

stat.ME

Teasing out the overall survival benefit with adjustment for treatment switching to other therapies

In oncology clinical trials, characterizing the long-term overall survival (OS) benefit for an experimental drug or treatment regimen (experimental group) is often unobservable if some patients in the control group switch to drugs in the experimental group and/or other cancer treatments after disease progression. A key question often raised by payers and reimbursement agencies is how to estimate the true benefit of the experimental drug group on overall survival that would have been estimated if there were no treatment switches. Several commonly used statistical methods are available to estimate overall survival benefit while adjusting for treatment switching, ranging from naive exclusion or censoring approaches to more advanced methods including inverse probability of censoring weighting (IPCW), iterative parameter estimation (IPE) algorithm or rank-preserving structural failure time models (RPSFTM). However, many clinical trials now have patients switching to different treatment regimens other than the test drugs, and the existing methods cannot handle more complicated scenarios. To address this challenge, we propose two additional methods: stratified RPSFTM and random-forest-based prediction. A simulation study is conducted to assess the properties of the existing methods along with the two newly proposed approaches.

stat.AP